JPMorgan Reinstates BeOne Medicines (ONC) at Overweight

JPMorgan analyst Jessica Fye reinstates coverage on BeOne Medicines (NASDAQ: ONC) with a Overweight rating and a price target of $415.00.

For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.

Shares of BeOne Medicines closed at $297.01 yesterday.

You May Also Be Interested In

• Lake Street Starts Vivani Medical, Inc. (VANI) at Buy
• Canaccord Resumes Calian Group Ltd (CGY:CN) (CLNFF) at Buy
• CLSA Starts Vedanta Aluminium Metal (VAML:IN) at Outperform (2)